Evaluating the performance of polygenic risk profiling across diverse ancestry populations in Parkinson’s disease

Paula Saffie-Awad; Inas Elsayed; Arinola O. Sanyaolu; Peter Wild Crea; Artur F Schumacher Schuh; Kristin S Levine; Dan Vitale; Mathew J Korestky; Jeffrey Kim; Thiago Peixoto Leal; María Teresa Periñan; Sumit Dey; Alastair J Noyce; Armando Reyes-Palomares; Noela Rodriguez-Losada; Jia Nee Foo; Wael Mohamed; Karl Heilbron; Lucy Norcliffe-Kaufmann; the 23andMe Research Team; Mie Rizig; Njideka Okubadejo; Mike Nalls; Cornelis Blauwendraat; Andrew Singleton; Hampton Leonard; Mary B Makarious; Ignacio F. Mata; Sara Bandres-Ciga; the Global Parkinson’s Genetics Program (GP2)

doi:10.1101/2023.11.28.23299090

Data and Code Availability

Data were obtained from the Global Parkinson’s Genetics Program (GP2) and is accessible through a partnership with the Accelerating Medicines Partnership in Parkinson’s Disease (AMP-PD) and can be requested via the website’s application process (https://www.amp-pd.org/). GWAS summary statistics from GP2’s release 5 are available for all datasets (release 5; doi:10.5281/zenodo.7904832). 23andMe summary statistics is available upon application through their website (https://research.23andme.com/dataset-access/). GenoTools (version 10; https://github.com/GP2code/GenoTools) was used for genotyping, imputation, quality control, ancestry prediction, and data processing. A secured workspace on the Terra platform was created to conduct genetic analyses using GP2 release 5 data and summary statistics (https://app.terra.bio/). Additionally, all scripts used for this study can be found in the public domain on GitHub (https://github.com/GP2code/GP2-Multiancestry-PRS; doi:10.5281/zenodo.10211779).